-
Novo Nordisk's new online chatbot, available 24/7 for diabetes questions
fiercepharma
September 19, 2018
Say hello to Sophia, Novo Nordisk's new online chatbot, available 24/7 for diabetes questions
-
U.S. Deaths From Suicide, Drugs Surpass Diabetes
drugs
August 28, 2018
More Americans are now dying from suicide and drug overdoses combined than from diabetes, a new report reveals.
-
Ozempic consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
firstwordpharma
August 27, 2018
Munich, Germany, 26 August 2018 - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack......
-
Predicting the risk of heart disease, diabetes and more using millions of gene variants
fiercebiotech
August 14, 2018
If physicians could predict which of their patients are more likely to develop serious diseases like breast cancer, type 2 diabetes and coronary artery disease, they could offer personalized preventive care that’s only minimally available today.
-
Sanofi diabetes executive makes the jump to Omeros to become CMO
fiercebiotech
August 03, 2018
In keeping with the recent trend of top R&D executives moving to smaller biotechs, Sanofi’s Eckhard Leifke, M.D., the giant’s global head of diabetes late-stage development......
-
MannKind signs distribution deal with Tanner for diabetes drug
pharmaceutical-technology
August 01, 2018
US-based therapeutic products developer MannKind has signed an agreement with Tanner Pharma Group for the distribution of its Afrezza Inhalation Powder in countries outside the US.
-
Pfizer drops diabetes and cancer drugs from clinical pipeline
fiercebiotech
August 01, 2018
Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase pipeline (PDF). The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
-
Lilly and Sigilon partner to develop diabetes type I therapies
pharmatimes
July 18, 2018
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for type I diabetes.
-
Diabetes Diagnosis 'Silver Lining'? Other Family Members' Health May Improve
drugs
July 10, 2018
A new study found that partners of people newly diagnosed with diabetes were 50 percent more likely to attend weight management classes and 25 percent more likely to get medication to help quit smoking.
-
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction
pharmatimes
July 05, 2018
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.